Farnesyl transferase inhibitors as anticancer agents

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Protein farnesylation is a post-translational modification crucial for the function of G-proteins like Ras, Rho, and lamins.
• Activated Ras proteins are key mediators in cell signaling pathways regulating survival (PI3K/AKT) and proliferation (Raf/MEK/ERK).
• Mutations leading to constitutively active Ras proteins are implicated in approximately 30% of human cancers.

Purpose of the Study:

• To review the clinical data of farnesyl protein transferase inhibitors (FTIs) as anticancer agents.
• To explore the mechanisms of action of FTIs, particularly concerning their impact on Ras function and broader anticancer activity.
• To discuss the current status of three FTIs undergoing clinical trials.

Main Methods:

• Review of existing clinical trial data for three specific farnesyl transferase inhibitors.
• Analysis of the role of protein farnesylation in cell signaling and cancer proliferation.
• Evaluation of the evidence linking FTIs to Ras inhibition and other potential anticancer mechanisms.

Main Results:

• Farnesylation is essential for the transforming and proliferative activity of Ras proteins.
• FTIs were designed to inhibit Ras function, but clinical evidence suggests their anticancer efficacy may involve additional pathways.
• Clinical trial data for three FTIs are currently under evaluation.

Conclusions:

• Farnesyl protein transferase inhibitors represent a targeted therapeutic strategy for cancers with Ras mutations.
• The precise mechanisms underlying the anticancer effects of FTIs require further investigation beyond simple Ras inhibition.
• Ongoing clinical trials will provide critical insights into the efficacy and safety of these agents.